Assessment of Cardiac Safety for PPAR&ggr; Agonists in Rodent Models of Heart Failure: A Translational Medicine Perspective

Publisher： Bentham Science Publishers

E-ISSN： 1874-4702|5|2|264-271

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.5, Iss.2, 2012-06, pp. : 264-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PPAR-&ggr; Agonists as Regulators of Microglial Activation and Brain Inflammation

By  

Current Pharmaceutical Design, Vol. 12, Iss. 1, 2006-01 ,pp. : 93-109

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-06 ,pp. : 255-263

Bentham Science Publishers

Access to resources Recommend Favorite

Examining the safety of PPAR agonists - current trends and future prospects

By Bortolini Michele  

Expert Opinion on Drug Safety, Vol. 12, Iss. 1, 2013-01 ,pp. : 65-79

Informa Healthcare

Access to resources Recommend Favorite

Optimization of Cardiac Metabolism in Heart Failure

By  

Current Pharmaceutical Design, Vol. 17, Iss. 35, 2011-12 ,pp. : 3846-3853

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical Cardiac Safety Assessment of Drugs

By Hanton Gilles  

Drugs in R&D, Vol. 8, Iss. 4, 2007-01 ,pp. : 213-228

Adis International

Access to resources Recommend Favorite